{"id":692768,"date":"2022-10-06T07:22:44","date_gmt":"2022-10-06T11:22:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/"},"modified":"2022-10-06T07:22:44","modified_gmt":"2022-10-06T11:22:44","slug":"plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/","title":{"rendered":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dvDwEY9otb2PdWtg-eXqsCYXpB6jQ-DiutSQp5KOac3cb9hZA9PeXhZ-LAuKQw9mAk3p2wNKwFa-P_qQidjSxSnpn9cozokuucd2A1-CFHw=\" rel=\"nofollow noopener\" target=\"_blank\">Plus Therapeutics, Inc.<\/a> (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Z1PfDRTIuyrUI59Cn_sU2fizsjn6lcpKu9VO9WDnMKw0iCID9Fw2MQGgKZsmcw1zQEm7GbaVPVOLWewV8Sfy035KNFhR2pKNdiW9gJIO_0=\" rel=\"nofollow noopener\" target=\"_blank\">PSTV<\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">A live webcast will be available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a4LzvdcJ_aIdj4lrv13D1aUK3IYTKoQj7JK69Tnw4s0sw_CAdzYRAFynBy69u70DMYbPH1yRPHmuKC7U0P_dTNpgrAMclSI2fNWth2x6BN0u9GcZYcCP3_hWAEZnSqTH\" rel=\"nofollow noopener\" target=\"_blank\">ir.plustherapeutics.com\/events<\/a>.<\/p>\n<p align=\"justify\">Participants may also pre-register any time before the call <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=shh8mXk6hGlvfu_V8Wq3yN9dxI9ewVJffSR2Bhc_xaHy5VVHbI9TaIfVvgvJ9Yix787q59Ta-r29U8PNj94pF_5ahnHqlSxLjBUttafu_Kc8XLdFPkAFE3mOLn_0tQFWdecRalU_k57N5Sx07GA_KA==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.<\/p>\n<p align=\"justify\">Following the live call, a replay will be available on the Company\u2019s website under the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r0nkj_85BvpRj6y4OkrvwqMOWfJtLDpGrJsrgqqGAmdk_0WttzQsHVjqeUvaFyBNZclPK0NnWRWo_7Vmrq6m05V6pBRVV5cH2n1OXtm2cPo=\" rel=\"nofollow noopener\" target=\"_blank\">&#8216;For Investor&#8217;<\/a> section. The webcast will be available on the Company\u2019s website for 90 days following the live call.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <strong>About Plus Therapeutics, Inc.<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and\/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zesEwpJAYJ87SDwmZZcVL66V3ki67ok6SwLFYzaG_mqKfYqOQrtavgx3FVIGG3YzOd47nnsxknVhwIjDzAInVuxiIFAuzW5ZGXTtDOxFwBo=\" rel=\"nofollow noopener\" target=\"_blank\">PlusTherapeutics.com<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QarPsvlVdqBE1x2eAd7YLsUrsDdbGgQkEkWzBfc3nC-WHWpLbvDGzAii6dKoYmvOL_7rwXrmJGcb6q7cGSdNXBYzJ8HlUfNsy9pvzjmhydk=\" rel=\"nofollow noopener\" target=\"_blank\">ReSPECT-Trials.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains statements that may be deemed \u201cforward-looking statements\u201d within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as \u201cdesigned to,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cpotential,\u201d \u201cfocus,\u201d \u201cpreparing,\u201d \u201cnext steps,\u201d \u201cpossibly,\u201d and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of <sup>186<\/sup>RNL including the ability of <sup>186<\/sup>RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company\u2019s future performance including the next steps in developing the Company\u2019s current assets; the Company\u2019s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM trial; possible negative effects of <sup>186<\/sup>RNL; the continued evaluation of <sup>186<\/sup>RNL for LM including through evaluations via a second patient cohort; capital requirements, timing and speed of development; and the intended functions of the Company\u2019s platform and expected benefits from such functions.<\/p>\n<p align=\"justify\">The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company\u2019s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company\u2019s product candidates and therapies, the results of the Company\u2019s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company\u2019s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company\u2019s partnering\/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; changes in the CPRIT program; and additional risks described under the heading \u201cRisk Factors\u201d in the Company\u2019s Securities and Exchange Commission filings, including in the Company\u2019s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>ICR Westwicke<br \/>(443) 377-4767<br \/>Peter.Vozzo@westwicke.com<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Terri Clevenger<br \/>ICR Westwicke<br \/>(203) 856-4326<br \/>Terri.Clevenger@westwicke.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2FjMzdjYjAtNDczZi00YjA3LWE1YmUtN2VmNTNkM2Y2Y2I2LTEwMTYzNzg=\/tiny\/Plus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com\/events. Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692768","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com\/events. Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the &hellip; Continue reading &quot;Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T11:22:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022\",\"datePublished\":\"2022-10-06T11:22:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/\",\"name\":\"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\",\"datePublished\":\"2022-10-06T11:22:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/","og_locale":"en_US","og_type":"article","og_title":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk","og_description":"AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics\u2019 management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. A live webcast will be available at ir.plustherapeutics.com\/events. Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the &hellip; Continue reading \"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T11:22:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022","datePublished":"2022-10-06T11:22:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/","name":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=","datePublished":"2022-10-06T11:22:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTg5OCM1MTkwMDU3IzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-october-20-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692768"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}